

GNVPN.019B1USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 09/757,673

Confirmation No.: 8771

Applicant

: James M. Wilson et al

Filed

: January 10, 2001

TC/A.U.

: 1632

Examiner

: R. Shukla

Customer No.

: 00270

Title

: METHOD FOR RECOMBINANT ADENO-

ASSOCIATED VIRUS-DIRECTED GENE THERAPY

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and after the receipt of a first Office Action on the merits. Therefore, a fee of \$180.00 is due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

11/12/2004 SSITHIB1 00000152 09757673 02 FC:1806

180.00 gp

The Examiner is respectfully requested to consider the enclosed document identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for Applicant

Cathy A Kodroff

Registration No. 33,980

Spring House Corporate Center

Box 457

Spring House, PA 19477 Phone: (215) 540-9200

Fax: (215) 540-5818

OIPE	
MOV 1 0 2004	Sudder the Paperwork Reduction

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

o.S. Patent and Trademark Office; D.S. Department of Commerci r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Sudder the	Paperwork	c Reduction Act of 1995, no p	ersons are required to respond to a c	ollection of information unless it contains a valid OMB control number.	
, E				Complete if Known		
28 UPSTITUTE	10 form 1449	/РТО	,	Application Number	09/757,673	
INFO	DRMATI	ON [DISCLOSURE	Filing Date	January 10, 2001	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	James M. Wilson et al	
((Use as many sheets as necessary)			Group Art Unit	1632	
				Examiner Name	R. Shukla	
Sheet	1	of	2	Attorney Docket Number	GNVPN.019B1USA	

U.S. PATENT DOCUMENTS						
Examiner	Cite No.1	Document Number	Publication Date		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*		Number-Kind Code ^{2(if known)}	MM-DD-YYYY			
	BBU	US-6,093,534	07-25-2000	Shimada et al		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6	
		Country Code Hamper Time Gode (Wilson)					

Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

NOV 1 0 2004 5

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control numb

	£/				Complete if Known
PADE	of form	1449/PTO		Application Number	09/757,673
INF	ORMA	TION	DISCLOSURE	Filing Date	January 10, 2001
STA	TEME	NT BY	APPLICANT	First Named Inventor	James M. Wilson et al
				Group Art Unit	1632
į	(Use as ma	any sheets a	as necessary)	Examiner Name	R. Shukla
Sheet	2	of	2	Attorney Docket Number	GNVPN.019B1USA

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BBV	JOHNSON ET AL, RAAV Vectors as Novel HIV-1 Vaccine	
		Candidates: Immunogenicity in Non-Human Primates, Gene	
		Therapy Applications (Session 2C), Xth Parvovirus Workshop, St.	
		Petersburg, FL, September 8-12, 2004	
	BBW	ZHI ET AL, Increased Antigen-Specific Humoral Response by	
		Adenoviral Vector Prime and Adeno-Associated Viral Vector	
		Boost, 7 th Annual Meeting of the American Society for Gene	
		Therapy, June 2-6, 2004, Minneapolis, Minnesota, e-publ. May 3,	
		2004	
	<u></u>		
	<u> </u>		
	<u></u>		
	7		

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if on in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.

Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.